EndocrinologyAdvisor

@EndoAdvisor

Endocrinology Advisor provides healthcare professionals with comprehensive information and clinical news on the management of endocrine conditions.

New York, NY

Joined March 2014

339Following

3KFollowers

EndocrinologyAdvisor@EndoAdvisor · Jul 25

A #ReproductiveEndocrinologist was sued for #MedicalMalpractice after a patient received a diagnosis of #OvarianCancer after undergoing #FertilityTreatment. endocrinologyadvisor.com/features/ovari…

EndoAdvisor's tweet card. A reproductive endocrinologist was found liable in a medical malpractice lawsuit after failing to diagnose a patient with ovarian cancer.

EndocrinologyAdvisor@EndoAdvisor · Jul 25

#CentralPrecociousPuberty elevated risk for #MentalDisorders as early as 1 year before diagnosis and up to 8 years after diagnosis. endocrinologyadvisor.com/news/central-p…

EndoAdvisor's tweet card. Central precocious puberty was associated with elevated risk for psychiatric disorders including depression, ADHD, and anxiety.

EndocrinologyAdvisor@EndoAdvisor · Jul 25

#Amputation risk was significantly reduced among patients with #T2D who used #GLP1RAs compared with #SGLT2is. @IvanYLuu @DGArmstrong @TzeWoeiTan @usc_vascular @KECKSchool_USC endocrinologyadvisor.com/news/glp-1ras-…

EndoAdvisor's tweet card. GLP-1RAs were associated with significantly reduced risk for amputations relative to SGLT2is among patients with type 2 diabetes.

EndocrinologyAdvisor@EndoAdvisor · Jul 24

Still catching up on research from #ENDO2025? Find all of Endocrinology Advisor's coverage from this month's conference below ⬇️ @TheEndoSociety endocrinologyadvisor.com/conferences/en…

EndoAdvisor's tweet card. Presenting research from ENDO, the annual meeting of the Endocrine Society.

EndocrinologyAdvisor@EndoAdvisor · Jul 22

Pre-visit patient activation enhanced the positive effect of PCP academic detailing on diabetes #deprescribing rates among older adults with #T2D. @klipskaMD @KPDOR @YaleMed endocrinologyadvisor.com/news/academic-…

EndoAdvisor's tweet card. Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.

EndocrinologyAdvisor@EndoAdvisor · Jul 22

Reduced heavy menstrual bleeding was sustained with #linzagolix therapy, regardless of adjunct hormonal add-back therapy, at 1 year among patients with #UterineFibroids. endocrinologyadvisor.com/news/linzagoli…

EndoAdvisor's tweet card. Linzagolix therapy was associated with significantly reduced heavy menstrual bleeding by week 52 among patients with uterine fibroids.

EndocrinologyAdvisor@EndoAdvisor · Jul 21

Relative to #GLP1RA and #DPP4Inhibitor use, #SGLT2Inhibitor use was associated with an increased risk for #erythrocytosis but not an increased risk for #thrombosis in #T2D. endocrinologyadvisor.com/news/sglt2-inh…

EndoAdvisor's tweet card. SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.

EndocrinologyAdvisor@EndoAdvisor · Jul 21

Changes in #BoneMineralDensity were mediated by changes in E2 and testosterone among women and men, respectively, with #T2D undergoing weight loss. @Chigolum_Oyeka @ErinMichos endocrinologyadvisor.com/news/weight-lo…

EndoAdvisor's tweet card. Weight loss-induced sex hormone changes had a mediating effect on bone mineral density loss among patients with type 2 diabetes.

EndocrinologyAdvisor@EndoAdvisor · Jul 21

We spoke with #endocrinologists to explore the potential of #ArtificalIntelligence in the management of #ChronicDisease, including #diabetes, #obesity, and #PCOS. @BIDMChealth @dcihmfp @Visana_Health @MassGeneralNews endocrinologyadvisor.com/features/chron…

EndoAdvisor's tweet card. AI offers promise in the realm of chronic disease management, including diabetes, obesity, and PCOS, but must be approached with caution.

EndocrinologyAdvisor@EndoAdvisor · Jul 18

From #ENDO2025: There are significant reductions in patient-reported symptom severity among patients with #acromegaly treated with #paltusotine. @TheEndoSociety @Crinetics endocrinologyadvisor.com/reports/paltus…

EndoAdvisor's tweet card. Paltusotine treatment is associated with significant reductions in patient-reported symptom severity among patients with acromegaly.

EndocrinologyAdvisor@EndoAdvisor · Jul 18

#GestationalGlucoseIntolerance was associated with increased #obesity risk, especially among children aged 11 to 18 years. @tthaweethai @CEPoweMD endocrinologyadvisor.com/news/gestation…

EndoAdvisor's tweet card. Gestational glucose intolerance was associated with increased risk for obesity and overweight, especially among children aged 11 to 18 years.

EndocrinologyAdvisor@EndoAdvisor · Jul 18

From #ENDO2025: #Veligrotug vs placebo was associated with significant improvements in #proptosis, #diplopia, and clinical activity score in active #ThyroidEyeDisease. @TheEndoSociety @drzhangnunes @ThomasCiullaMD endocrinologyadvisor.com/reports/veligr…

EndoAdvisor's tweet card. Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

EndocrinologyAdvisor@EndoAdvisor · Jul 17

From #ENDO2025: Among #tirzepatide users, women experienced greater reductions in total #cholesterol, LDL cholesterol, and weight than men. @TheEndoSociety @dimaMBch @Reginacastamd @marantoec @dr_aac @StephFaubionMD @cshufeltMD endocrinologyadvisor.com/reports/tirzep…

EndoAdvisor's tweet card. Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

171

EndocrinologyAdvisor@EndoAdvisor · Jul 17

From #ENDO2025: #DiazoxideCholine extended-release tablets for #hyperphagia demonstrated favorable #glycemic safety across 4 years among patients with #PraderWilliSyndrome. @TheEndoSociety @shoemakerendo @efgevers endocrinologyadvisor.com/reports/diazox…

EndocrinologyAdvisor@EndoAdvisor · Jul 17

From #ENDO2025: #BariatricSurgery #WeightLoss outcomes were comparable between adolescent girls with and without #PCOS. @TheEndoSociety @jryder1123 @drtominge @LTorchen endocrinologyadvisor.com/reports/adoles…

EndoAdvisor's tweet card. Adolescents with PCOS demonstrated comparable weight loss to their reproductively normal peers after undergoing bariatric surgery.

EndocrinologyAdvisor@EndoAdvisor · Jul 16

From #ENDO2025: #ThyroidCancer attributable to high #BMI has increased from 1990 to 2021, especially among older adults and men. @TheEndoSociety @aishwar_dixit endocrinologyadvisor.com/reports/thyroi…

EndoAdvisor's tweet card. Thyroid cancer burden attributable to high BMI was increasing between 1990 and 2021 in the US, especially among men and older adults.

184

EndocrinologyAdvisor@EndoAdvisor · Jul 16

From #ENDO2025: Presence of #AdrenalAdenoma was associated with lower #WeightLoss among patients with #obesity using #GLP1 or GIP/GLP-1 receptor agonists. @TheEndoSociety @leili_rahimi @JaimeAlmandoz @UTSWMedCenter endocrinologyadvisor.com/reports/adrena…

EndoAdvisor's tweet card. Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP-1 RAs.

EndocrinologyAdvisor@EndoAdvisor · Jul 16

From #ENDO2025: #Tirzepatide was superior to #semaglutide in achieving standard and intensive #cardiometabolic targets among patients with #T2D. @TheEndoSociety endocrinologyadvisor.com/reports/tirzep…

EndoAdvisor's tweet card. Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

EndocrinologyAdvisor@EndoAdvisor · Jul 15

From #ENDO2025: Glucopilot dynamic dosing algorithm improved #glycemia management, especially among patients with #DiabeticKetoacidosis, #sepsis, and #steroid use. @TheEndoSociety @HopkinsMedicine @HonorHealth endocrinologyadvisor.com/reports/glucop…

EndoAdvisor's tweet card. Glucopilot dynamic dosing algorithm was associated with improved glycemic control especially among subgroups with hard-to-manage glycemia.

EndocrinologyAdvisor@EndoAdvisor · Jul 15

From #ENDO2025: In pediatric #CongenitalAdrenalHyperplasia, #crinecerfont is associated with sustained reductions in #androstenedione levels and #glucocorticoid doses at 1 year. @TheEndoSociety endocrinologyadvisor.com/reports/crinec…

EndoAdvisor's tweet card. Crinecerfont is associated with sustained reductions in androstenedione and GC doses at 1 year in congenital adrenal hyperplasia.